Medicine
Adverse Drug Reactions and Pharmacovigilance
Quick fact
An estimated 5% of all serious adverse drug reactions are ever reported to national pharmacovigilance systems, which is why so many hidden harms take years to surface.
Why this is interesting
You trust a drug you take because it passed clinical trials—but those trials can miss life-threatening dangers for the very first time. How do we catch a medication's hidden harms after it is already in pharmacy shelves?
Read the full explanation
Understanding Adverse Drug Reactions and Pharmacovigilance
An adverse drug reaction is any harmful and unintended response to a medicine when it is used at normal doses. It is not a deliberate overdose or an accidental poisoning; it happens at everyday therapeutic doses. A side effect is a broader term—any effect beyond the intended one, which may be harmless. ADRs are the dangerous subset of side effects. Pharmacovigilance is the science of looking after medicines after they reach the public. When a doctor, pharmacist, or patient suspects a drug caused harm, they file a report to a national agency. These reports are pooled into databases. If a particular harm appears more often than expected, analysts identify a 'signal'—a possible new risk. This triggers deeper investigation and, if confirmed, regulatory action such as changing the label, warning prescribers, or removing the drug. The system exists because pre-approval trials have limits. They test a few thousand people for a relatively short time, and those people are carefully selected—often excluding children, the elderly, pregnant women, and people with other diseases. Rare but serious effects may only appear when a drug is used by millions of diverse patients.
A deeper explanation
Pharmacovigilance works because it turns scattered individual tragedies into statistical patterns. It relies on reporting, data aggregation, signal detection, and regulatory action. ADRs are broadly classified into two main types. Type A (augmented) reactions are dose-dependent, predictable from the drug's known pharmacology, and usually mild—for example, a beta-blocker causing excessive slowing of the heart. Type B (bizarre) reactions are dose-independent, unpredictable, and often allergic or idiosyncratic in origin—for example, an antibiotic triggering a severe anaphylactic reaction. Type B reactions are especially dangerous because they cannot be anticipated and may appear after a single small dose. The historic catalyst for pharmacovigilance was the thalidomide disaster of the 1950s–1960s. Thalidomide, marketed as a mild sedative, was also taken by pregnant women for morning sickness. It caused severe birth defects (phocomelia) in thousands of babies. This tragedy revealed that premarket testing alone could not protect the public, and it led to the birth of formal drug safety monitoring systems around the world. Modern pharmacovigilance uses large databases like the WHO's VigiBase, which holds millions of case reports. Analysts use methods like proportional reporting ratios to detect disproportionate reporting of a drug-adverse event combination. A signal, however, is only a hypothesis—it must be validated with epidemiological studies and biological evidence. The ultimate goal is not alarm but balance: maintaining a medicine's benefits while minimizing harm through dosage adjustments, warnings, and in rare cases, withdrawal.